Summary & Overview
CPT 86654: Immunoassay for Western Equine Encephalitis Antibodies
CPT code 86654 represents a laboratory immunoassay for antibodies to Western equine encephalitis virus (WEE) performed on serum or cerebrospinal fluid. This code matters nationally as part of infectious disease surveillance and diagnostic workflows for arboviral encephalitis, supporting clinical decision-making and public health reporting. Laboratories and clinicians use this test in patients with suspected encephalitic illness where WEE is in the differential.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and billing practices for high-complexity or low-volume infectious disease serologies can vary across national payers, affecting prior authorization, medical necessity documentation, and reimbursement adjudication.
Readers will learn the clinical context for use of CPT code 86654, the typical service setting, and common billing considerations tied to serologic testing for arboviral infections. The publication outlines benchmark elements, payer landscape, and policy-relevant points that influence laboratory utilization and claims handling. Data not available in the input is noted where specific payer policies, reimbursement rates, and associated taxonomies or ICD-10 mappings would normally be provided.
Billing Code Overview
CPT code 86654 describes an immunoassay performed by a laboratory analyst to detect antibodies to Western equine encephalitis virus (WEE) in a patient’s serum or cerebrospinal fluid. The test identifies the presence of specific antibodies that indicate current or prior immune response to WEE infection.
Service type: Laboratory diagnostic immunoassay
Typical site of service: Clinical laboratory or hospital laboratory (testing on serum or cerebrospinal fluid samples)
Clinical & Coding Specifications
Clinical Context
A patient presents to the emergency department in late summer with acute onset fever, headache, malaise, and confusion after recent outdoor exposure in an area where arboviral activity is possible. The emergency physician documents an acute encephalitic syndrome and orders urgent laboratory testing to evaluate for arboviral causes. The clinical laboratory receives a serum specimen and, when clinically indicated, cerebrospinal fluid (CSF) from lumbar puncture performed by the admitting team. The laboratory technologist performs an immunoassay to detect IgM and/or IgG antibodies directed against Western equine encephalitis virus (WEE) using validated serologic methods. Results are reviewed by the laboratory director and reported to the ordering clinician; positive or equivocal results may prompt confirmatory testing (neutralization assays or PRNT) and notification of public health authorities. Typical workflow steps include specimen collection and labeling, transport to the laboratory, accessioning, performance of the immunoassay, quality control, result interpretation, result verification by laboratory medical staff, and electronic reporting to the clinician and public health as required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation/reporting portion of a technical test performed by another entity. |